MACE prediction in patients with STEMI and NSTEMI: from classic to novel markers in the estimation of coronary microcirculation disorder
DOI:
https://doi.org/10.52692/1857-0011.2024.1-78.01Keywords:
STEMI, NSTEMI, MACE, classic markers, new markers, predictorsAbstract
Aim. Evaluation of classic and novel markers of coronary microcirculatory disorder (CMD) which have a predictive value on the risk of major cardiovascular event (MACE) in patients with STEMI and NSTEMI. Material and methods. The research included the retrospective analysis of a prospective observational study carried out on 600 patients, of which have been formed equal 4 groups of 80 patients (STEMI+MACE; STEMI-MACE; NSTEMI+MACE; NSTEMI-MACE) in which the collected blood on the 5-th day after angioplasty, the circulating level of 16 markers referring to CMD in the field of estimating endothelial dysfunction and hemostasis was determined: 8 classic markers (hsCRP, IL-6, TNF-α, IL-10, myeloperoxidase, NO , angiopoietin 2, fibrin monomers) and 8 new markers (neopteirn, endocan, syndecan 1, L-Arginine/ADMA, Ang 1-7/Ang II, endothelial microparticles, platelet microparticles, von Willebrand/ADAMTS13). In order to assess the prediction of MACE (cardiac death, re-infarction, stroke) at 1-st year, the relative risk of markers that had significant differences in patients with MACE versus without MACE in both groups (STEMI and NSTEMI) was assessed. The control group consisted of 40 apparently healthy people. Results. The MACE rate in STEMI and NSTEMI patients at 1 year was similar, 29% and 28%, respectively. All markers of endothelial dysfunction explored had significant deviations from control. Of these, however, only 4 markers had significant different values in patients (STEMI and NSTEMI) with MACE vs without MACE: neopterin, endocan, L-Arginine/ADMA and Ang 1-7/Ang II. Remarkably, all 3 markers of hemostasis explored had circulating levels in patients who developed MACE significantly higher than patients without MACE, which significantly exceeded the control marker. The assessment of the relative risk value has allowed the delineation of markers regarding the prediction of MACE such as: von Willebrand/ADAMTS13, platelet microparticles, fibrin monomers, endocan, neopterin, Ang 1-7/ Ang II, L-Arginine/ADAMTS13. Conclusions. 1. Endothelial dysfunction and compromised hemostasis are pathophysiological pillars of CMD which influences the MACE risk, and thus new markers such as von Willebrand/ADAMTS13 ratio, platelet microparticles, endocan, the ratio Ang 1-7/Ang II and L/Arginine/ ADMAs have notable predictive value on MACE.2. Since CMD may be a key mechanism of cardiac ischemia in chronic non-obstructive coronary artery disease (<50%) its evaluation, including through the identified predictors, has a conclusive diagnostic and prognostic relevance.
References
Yang Z, Liu Y, Li Z et al. Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies. Biomedicine & Pharmacotherapy. 2023, 164, 115011, ISSN 0753-3322. https://doi.org/10.1016/j.biopha.2023.115011.
Takahashi S, Papafaklis M. Low endothelial shear stress predicts the progression of coronary artery disease with increasing plaque eccentricity: an in vivo natural history study of atherosclerosis in humans. European Heart Journal. 2012, 33(suppl 1):355. DOI:10.1093/eurheartj/ehs282.
Popovici M, Ivanov V, Popovici I et al. Panoul multi-marker la pacienții cu infarct miocardic acut fără supradenivelarea de segment ST: repere patogenetice și de diagnostic. Buletinul AȘM, Științe Medicale. 2023, 1(75): 33-40. DOI: https://doi.org/10.52692/1857-0011.2023.1-75.05.
Popovici M, Ivanov V, Popovici I et al. NET-OZA în infarctul miocardic acut fără elevarea segmentului ST: semnificații fiziopatologiceși markeri circulanți. Buletinul AȘM, Științe Medicale. 2023, 1(75): 17-23. DOI: https://doi.org/10.52692/1857-0011.2023.1-75.05.
Popovici M, Loffredo L, Ivanov V et al. Rolul disbiozei intestinale în disfuncția endotelială la pacienții cu angină microvasculară. Buletinul AȘM, Științe Medicale. 2023, 1(75): 7-16. DOI: https://doi.org/10.52692/1857-0011.2023.1-75.05.
Stătescu C, Anghel L, Tudurachi BS et al. From classic to modern prognostic biomarkers in patients with acute myocardial infarction. Int J Mol Sci. 2022, 23(16): 9168. doi: 10.3390/ijms23169168.
Chakrala T, Prakash R, Valdes C et al. Circulating Biomarkers in Coronary Microvascular Dysfunction. Journal of the American Heart Association. 2023, 2:e029341. https://doi.org/10.1161/JAHA.122.029341.
Rocco E, Grimaldi MC, maino A et al. Advances and Challenges in Biomarkers Use for Coronary Microvascular Dysfunction: From Bench to Clinical Practice. J Clin Med. 2022, 11(7): 2055. DOI: 10.3390/jcm11072055.
Awuah A, Moore JS, Nesbit MA et al. A novel algo- rithm for cardiovascular screening using conjunctival mi- crocirculatory parameters and blood biomarkers. Sci Rep. 2022, 12:6545. https://doi.org/10.1038/s41598-022-10491-7.
Reardon B, Pasalic L, Favaloro EJ et al. The intriguing relationships of von Willebrand factor, ADAMTS13 and cardiac disease. J Cardiovasc Dev. Dis. 2021, 8(9), 115. https://doi.org/10.3390/jcdd8090115.
Anderson RD, Pepine CJ. The coronary microcirculation in STEMI: the next frontier? European Heart Journal. 2015, 36, 3178–3181. doi:10.1093/eurheartj/ehv495.
Vaidya K, Tucker B, Patel S, Ng MKC. Acute Coronary Syndromes (ACS)—Unravelling Biology to Identify New Therapies—The Microcirculation as a Frontier for New Therapies in ACS. Cells. 2021, 10(9):2188. doi: 10.3390/cells10092188.
Ciobanu L, Popovici I, Ivanov V, Cobet V, Ivanov V, Popovici M. Diagnostic and prognostic value of neopterin and RNA-ase in patients with STEMI and NSTEMI. European Heart Journal. 2020, Volume 41, Issue Supplement 2. ehaa946.1681, https://doi.org/10.1093/ehjci/ehaa946.1681.
Vorobeva DA, Ryabov V, Lugacheva JG et al. Relationships between indicators of prothrombotic activity and coronary microvascular dysfunction in patients with myocardial infarction with obstructive and non-obstructive coronary artery disease. BMV Cardiovasc Disord. 2022, 22:530. doi: 10.1186/s12872-022-02985-z.
Kang MG, Koo B-K, Tantry US. Association between thrombogenicity indices and coronary microvascular dysfunction in patients with acute myocardial infarction. JACC Basic Transl Sci. 2021. 6(9–10): 749–761. doi:10.1016/j.jacbts.2021.08.007.eCollection2021Sep-Oct.
Wang K, Basu R, Poglitsch M, Bakal JA et al. Elevated Angiotensin 1–7/Angiotensin II ratio predicts favorable outcomes in patients with heart failure. Circulation: Heart Failure. 2020, 13(7):e006939. https:// doi.org/10.1161/CIRCHEARTFAILURE.120.006939.
Yu E, Ruiz-Canela M, Hu FB et al. Plasma Arginine/ Asymmetric Dimethylarginine Ratio and Incidence of Cardiovascular Events: A Case-Cohort Study. The Journal of Clinical Endocrinology & Metabolism. 2017, 102 (6):1879–1888. https://doi.org/10.1210/jc.2016-3569.
Cziraki A, Lenkey Z, Sulyok E et al. L-Arginine- Nitric Oxide-Asymmetric Dimethylarginine pathway and the coronary circulation: translation of basic science results to clinical practice. Front Pharamcol. 2020, 11:569914. doi: 103389/fphar.2020.569914.
Canu M, Khouri C, Marliere S et al. Prognostic significance of severe coronary microvascular dysfunction post-PCI in patients with STEMI: A systematic review and meta-analysis. PLOS ONE. 2021, 17(5):e0268330. https://doi.org/10.1371/journal.pone.0268330.
Alam S, Pepine CJ. Physiology and functional significance of the coronary microcirculation: An overview of its implications in health and disease. American Heart Journal Plus: Cardiology Research and Practice. 2024, 40:2024, 100381. https://doi.org/10.1016/j.ahjo.2024.100381.
Zhang W, Singh S, Liu L et al. Prognostic value of coronary microvascular dysfunction assessed by coronary angiography-derived index of microcirculatory resistance in diabetic patients with chronic coronary syndrome. Cardiovasc Diabetol. 2022, 21: 222. https://doi.org/10.1186/s12933-022-01653-y.
Downloads
Published
License
Copyright (c) 2024 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.